TSPO and Alzheimer disease: The first-generation radioligand [11C]PK-11195 was reported to lead to higher TSPO PET signals in the brains of patients with amyotrophic lateral sclerosis [32], Alzheimer’s disease [8], Parkinson’s disease [10] or individuals at risk of Huntington’s disease [33] compared to healthy controls.